Clinical Trials Logo

Pancreatitis, Chronic clinical trials

View clinical trials related to Pancreatitis, Chronic.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06386224 Not yet recruiting - Clinical trials for Chronic Pancreatitis

Internet-Delivered Pain Self-Management for Persons With Acute Recurrent and Chronic Pancreatitis Pain

IMPACT-2
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Severe and disabling abdominal pain is common in individuals with chronic pancreatitis. Although pain is associated with reduced quality of life and high economic and societal costs, there are limited effective options for pain management in this population. This study proposes an evidence-based psychological intervention approach using an internet-delivered pain self-management program to minimize the impact of pain and improve quality of life. The ultimate goal is to maximize the public health impact of the intervention with successful implementation and dissemination to pancreas clinics and to the community.

NCT ID: NCT06362187 Not yet recruiting - Clinical trials for Chronic Pancreatitis

VR Pilot for Pancreatitis

Start date: April 2024
Phase: N/A
Study type: Interventional

The purpose of the research is to test the feasibility and preliminary impact of a home-based, standardized, gut-directed, virtual reality cognitive behavioral therapy (VR CBT) on clinical and functional outcomes of patients with chronic pancreatitis (CP) and recurrent acute pancreatitis (RAP) pain. The primary research procedures are questionnaires and biometric Fitbit data. The study will enroll adult patients with CP or RAP.

NCT ID: NCT06358001 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

EchoTip AcuCore Post-Market Clinical Study

Start date: June 1, 2024
Phase:
Study type: Observational

The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.

NCT ID: NCT06205342 Not yet recruiting - Chronic Pain Clinical Trials

Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain

STEMCAP-1
Start date: May 1, 2024
Phase: Early Phase 1
Study type: Interventional

This protocol aims to test whether an infusion of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) can reduce pain associated with chronic pancreatitis (CP) and explore potential mechanisms of MSC action.

NCT ID: NCT06134024 Not yet recruiting - Clinical trials for Pancreatitis, Chronic

The Role of Double Pigtail Plastic Stents During Endoscopic Transmural Drainage of Pancreatic Fluid Collections.

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about clinical usefulness of double pigtail plastic stents during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of lumen-apposing metal stents (LAMS). The main question it aims to answer is: Does introduction of double pigtail plastic stents through the LAMS increases efficacy and safety of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections?

NCT ID: NCT05940987 Not yet recruiting - Clinical trials for Pancreatitis, Chronic

Phone-based Smoking Cessation Intervention for Patients With Chronic Pancreatitis.(START)

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This study aims to explore whether regular telephone intervention in patients with chronic pancreatitis can improve their smoking cessation rate.

NCT ID: NCT05899335 Not yet recruiting - Clinical trials for Chronic Pancreatitis

Feasibility Study of a Mobile Health App for Symptom Monitoring in People With Chronic Pancreatitis

SmartCP
Start date: November 2023
Phase: N/A
Study type: Interventional

Patients with chronic pancreatitis suffer from constant debilitating symptoms. They have complex needs and require specialist, multi-disciplinary care. The investigators have developed a mobile phone app for patients with chronic pancreatitis, called the SmartCP app - the first app of its kind for this patient group. What is SmartCP? SmartCP is an app that allows patients to log daily symptoms, diet, and physical activity for review at clinic. It creates a red-alert for action if there are worsening symptoms. A Monthly-Check-In feature looks for symptoms of new diabetes or pancreatic cancer. SmartCP provides education on every aspect of pancreatitis, as well as contact information for the clinical team and for important pancreatitis resources. To develop SmartCP, the investigators established a multidisciplinary steering committee. The study The investigators aim to conduct a feasibility study to determine if the SmartCP app is feasible in the management of patients with chronic pancreatitis, complementing current specialist healthcare. Specifically, they will investigate acceptability, retention, incidents, resources, app user statistics, as well as investigating the occurrence of crisis events, symptoms, escalating symptoms, new diagnoses of diabetes or pancreatic cancer, and the use of communication and education features.

NCT ID: NCT05778929 Not yet recruiting - Clinical trials for Pancreatitis, Chronic

Radiomic fEatures of Pancreas From Contrast Enhanced CT Image Predict One-Year RecUrrence Risk of Acute PancReatitis

RECUR
Start date: April 1, 2023
Phase:
Study type: Observational

One-year recurrence rate of acute pancreatitis at about 20%. 36% of the patients with recurrent acute pancreatitis will develop into chronic pancreatitis. In addition to negative impact on patient's quality of life, chronic pancreatitis is also associated with the occurrence of pancreatic cancer. The etiology of recurrent acute pancreatitis (RAP) can be divided into mechanical obstructive factors (e.g. cholelithiasis, cholestasis), metabolic abnormality and toxic substance factors (e.g. hyperlipidemia and alcoholism), and other or idiopathic factors. At present, the diagnosis and treatment of RAP remains highly challenging. Early identification and intervention on risk factors of recurrence will be effective in reducing incidence and improving prognosis. Contrast-enhanced Computed Tomography (CT) can not only provide more imaging information and further assess the severity of acute pancreatitis, but also aid in the differentiation of other diseases associated with acute abdominal pain. In addition, radiomics based on raw radiographic data has become a research hotspot in recent years. The purpose of this study is to establish and validate a deep learning model based on high concentration iopromide-enhanced abdominal CT images which is designed to predict the recurrence of pancreatitis in patients with first episode of pancreatitis within the 1-year follow-up period.

NCT ID: NCT05771675 Not yet recruiting - Clinical trials for Chronic Pancreatitis

Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis

SMV in CP
Start date: January 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this pilot study to examine the feasibility and acceptability of simvastatin in adults with Recurrent Acute Pancreatitis (RAP) and Chronic Pancreatitis (CP).

NCT ID: NCT05540197 Not yet recruiting - Diabetes Mellitus Clinical Trials

Arginine-stimulated Prediction of Early Outcome After Islet Transplantation

ALADDIN
Start date: October 2022
Phase:
Study type: Observational

Through islet transplantation, functional β-cell mass can be restored. Allogeneic islet transplantation is a treatment modality for a select group of patients with complicated type 1 diabetes mellitus. For patients undergoing (partial) pancreas resection, autologous islet transplantation may help prevent complicated diabetes. Up until now, no studies have been performed on early islet graft function in the first week after transplantation. Early graft function may be a predictor for estimating long-term islet graft success. Arginine can excite β-cells to release insulin. It can thus provide an estimate of β-cell secretory capacity and can be used as an alternative to (oral) glucose tolerance tests. In this study, we aim to find a predictor model for islet graft function by assessing peak C-peptide after arginine stimulus in the early post-transplantation phase.